Suppression of matrix metalloproteinase-2 and -9 mediated invasiveness by a novel matrix metalloproteinase inhibitor, BE16627B

Cell invasion is a nature of malignant gliomas, demeriting to many efforts of the treatment. Matrix metalloproteinase (MMP) is acknowledged as a key factor in this complicated process. The aim of this study was to investigate whether inhibition of MMP activity in malignant glioma cells could be achi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 2001-03, Vol.52 (1), p.1-9
Main Authors: WATANABE, Kunihiro, YOSHIDA, Daizo, NOHA, Masahiro, TERAMOTO, Akira
Format: Article
Language:English
Subjects:
Antineoplastic agents
Antineoplastic Agents - pharmacology
Biological and medical sciences
Chemotherapy
Collagen Type IV - metabolism
Coloring Agents
Dipeptides - pharmacology
Glioma - pathology
Glioma - physiopathology
Humans
Matrix Metalloproteinase 2 - physiology
Matrix Metalloproteinase 9 - physiology
Medical sciences
Neoplasm Invasiveness
Neurology
Pharmacology. Drug treatments
Protease Inhibitors - pharmacology
Succinates - pharmacology
Tetrazolium Salts
Thiazoles
Tumor Cells, Cultured
Tumors of the nervous system. Phacomatoses
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cell invasion is a nature of malignant gliomas, demeriting to many efforts of the treatment. Matrix metalloproteinase (MMP) is acknowledged as a key factor in this complicated process. The aim of this study was to investigate whether inhibition of MMP activity in malignant glioma cells could be achieved by a novel agent, BE16627B (BE). Malignant glioma cell lines, U87MG, U251MG, and U373MG, were employed to evaluate inhibitory effect on zymogram, type IV collagenolysis assay, and haptoinvasion assay for 24 h exposure of BE, following preliminar
ISSN:0167-594X
1573-7373
DOI:10.1023/A:1010639313832